BIOMERIEUX’S MISSING X-FACTOR (ADD; 14% UPSIDE)
21/06/22 -" With the double-whammy of waning pandemic-driven opportunities and the markets becoming increasingly-wary of high P/E MedTechs, testing stocks are having a tough time. One of the biggest victims of ..."
Pages
64
Language
English
Published on
21/06/22
You may also be interested by these reports :
18/04/24
While the near-term performance is expected to be impacted by various challenges, there are still some promising takeaways from our recent discussion ...
16/04/24
Drägerwerk reported softer-than-expected Q1 24 numbers, with sales declining by 2.6%. As expected, growth in the safety segment partly offset the ...
15/04/24
The FY23 reported EPS came in ahead of our expectations, as the firm more than offset the H2 23 wage inflation with very strong profit margin ...
15/04/24
Investor appetite for Merck KGaA (Add, Germany) shares has been somewhat subdued since we last teased the name (15/03/2021). At that time, the ...